diabetes medications

by Mark Morgan on August 24, 2010

in Endocrine

Tagged as: , ,

summary, references, & relevant links
This decision tool is intended to help select medications for diabetes on the basis of liver and renal function/impairment. From the International Diabetes Center’s Staged Diabetes Management Recommendations, 4th Edition.
Medication interactions may exist. This tool does not analyze the medications you choose, it only provides you with options based on the assessments you submit.
Cost information: Treatment Guidelines from The Medical Letter • Vol. 6 (Issue 71) • July 2008.
HbA1c reduction information: Staged Diabetes Management • 4th Edition • 2007.
A separate calculator for Child-Pugh Score in Liver Disease is at http://www.soapnote.org/digestive-system/child-pugh-score/

—————————————————————————

  • maintained at soapnote.org.
    expected HbA1c reduction: 1-2%; cost: $55/month
    expected HbA1c reduction: 1-2%; cost: $18/month (glyburide), $15.90/month (glipizide), $10.20/month (glimeperide)
    expected HbA1c reduction: 1-2%; cost: $132.30/month
    expected HbA1c reduction: ~1%, cost: $180.60/month
    expected HbA1c reduction: 0.5-1%, cost: $92.70/month (acarbose), $89.10/month (miglitol)
    expected HbA1c reduction: 1-2%, cost: $143.10/month (repaglinide), $138.60/month (nateglinide)
    expected HbA1c reduction: to less than 7%, cost: ~$90/month (rapid acting), ~$46/month (regular), $47/month (intermediate acting), ~$91/month (long acting)

Result - Paste this into your EHR:

GD Star Rating
loading...

Bookmark this Soapnote
LoadingFavoriteAdd to favorite soapnotes


Share this Soapnote
Share
Email this